Tilray(US:TLRY) Globenewswire·2025-12-18 19:07Core Insights - Tilray Medical is set to enhance its U.S. medical cannabis operations following federal cannabis rescheduling, indicating a significant shift in the healthcare landscape [1][2] - The formation of Tilray Medical USA, Inc. reflects the company's commitment to innovation and growth in the medical cannabis sector [1][4] Regulatory Developments - The rescheduling of cannabis by President Trump is viewed as a necessary evolution of U.S. federal policy, aligning regulation with scientific and medical data supporting cannabis use [2] - This regulatory change is expected to create a more credible foundation for medical cannabis research and clinical development, facilitating an integrated state-federal medical cannabis framework [2] Company Strategy and Operations - Tilray Medical has established a strong presence in regulated medical cannabis markets globally, offering over 200 registered products and serving over 500,000 patients [3] - The company plans to expand collaborations with healthcare operators and medical professionals, ensuring compliance with emerging regulatory guidelines [4] - Tilray Medical USA aims to introduce medical-grade cannabis products based on real-world data and insights from international operations [4] Market Position and Expertise - With a mature compliance infrastructure and deep scientific expertise, Tilray Medical is well-positioned to adapt to regulatory changes while maintaining high standards of patient safety and operational integrity [4] - The company has dedicated years to developing the necessary infrastructure and regulatory skills to operate responsibly in federally legal medical cannabis markets [2][3]